Please ensure Javascript is enabled for purposes of website accessibility

Why Celldex Therapeutics, Inc. Fell on Monday

By Cory Renauer – Updated Oct 22, 2018 at 3:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A big loss despite a lack of news for the precommercial biotech.

What happened

Shares of Celldex Therapeutics, Inc. (CLDX -0.51%), a clinical-stage biotech developing novel cancer therapies, fell 21.4% during midday trading on Monday despite a complete lack of news. As of 2:57 p.m. EDT, the stock was down 11.9%, possibly because investors were concerned the company had nothing worth mentioning to present this month's biggest oncology conference. 

So what 

Although it's hardly significant, investors can't be pleased with Celldex Therapeutics occupying a booth at the European Society of Medical Oncology's annual meeting over the weekend without sharing any new data. Although the company's former lead program cratered earlier this year, the company still has four candidates in clinical-stage trials.

Businessman lying face down on a sidewalk while holding a briefcase.

Image source: Getty Images.

When Celldex last provided an update, in August, investigators were still enrolling patients in a phase 2 trial with CDX-3379 and Erbitux to see if the combination could defeat head and neck tumors. The company's also enrolling patients with a variety of solid tumors into a phase 1 study with its CD40 targeted candidate, CDX-1140.

Now what

Running clinical trials is expensive, and moving CDX-3379 and CDX-1140 forward could lead to increased expenses in the quarters ahead. The company finished June with just $114 million in cash after operations lost $20 million during the three months ended June.

Celldex believes the cash it had on hand at the end of June, plus sales of its own shares can see it through 2020. With a bit of luck, ongoing studies will give investors a reason to boost the stock again before it needs to issue too many new shares.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Celldex Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics Stock Quote
Celldex Therapeutics
$36.90 (-0.51%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.